BridgeMD
Tests treatment safety and results for Acute Lymphoblastic Leukemia
Official title Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
ClinicalTrials.gov ID: NCT06886074
What this study is testing
What is Short course of blinatumomab?
Short course of blinatumomab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute lymphoblastic leukemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Detectable measurable residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) for overall survival (OS) and disease-free survival (DFS). Patients who are MRD positive and have no access to novel immunotherapies should receive an allogeneic hematopoietic stem cell transplantation (HSCT).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 16 to 60
You may be able to join if
- Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
- MRD detectable in complete response (above the limit of quantification according to FCM)
- Performance status 0-2 on the ECOG scale
- No prior organ damage
- Having a potential related or unrelated donor
You likely can't join if
- Performance status on the ECOG scale \>2
- HCT-CI \>3 points
- Patients who do not wish to participate in clinical study.
- Active central nervous system infiltration (CNS3)
- Active extramedullary disease
- Having previously received blinatumomab
See the full eligibility criteria
- Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
- MRD detectable in complete response (above the limit of quantification according to FCM)
- Performance status 0-2 on the ECOG scale
- No prior organ damage
- Having a potential related or unrelated donor
- Performance status on the ECOG scale \>2
- HCT-CI \>3 points
- Patients who do not wish to participate in clinical study.
- Active central nervous system infiltration (CNS3)
- Active extramedullary disease
- Having previously received blinatumomab
- Absence of related or unrelated donors
The study team makes the final eligibility decision.
Where it's taking place
- Monterrey, Nuevo León, Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 16 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Monterrey, Nuevo León, Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.